Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Verdict
Mostly mechanism / observational
Top outcomes
Liquid EPs 7630: 30 drops three times daily for adults during an acute infection
spread-through-day
Liquid extract (EPs 7630)
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
Days 4-7 of an acute episode
Within the acute illness window
During use
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
Pelargonium sidoides extract for treating acute respiratory tract infections.
Cochrane Database Syst Rev (2013) · Systematic review · n=10 trials; ~746 adults and ~819 children
Liquid EPs 7630 showed effectiveness for acute bronchitis in both adults and children; tablets did not
Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.
Pediatr Int (2012) · Rct · n=220 children/adolescents
Significantly greater BSS reduction with EPs 7630 versus placebo (P<0.0001)
Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.
Wien Med Wochenschr (2010) · Rct · n=406 adults
All three active dose groups improved patient-reported outcomes versus placebo at day 7
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Tirzepatide has a higher evidence score (7.8/10 vs 6.5/10) and wins in 2 of 3 categories.
No known interactions between Pelargonium Sidoides and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.